What is MDMA therapy for PTSD?

MDMA therapy for PTSD (MDMA-AT) is an experimental treatment approach that combines a limited number of supervised MDMA dosing sessions with a structured course of psychotherapy, including preparation and integration sessions. The idea is that MDMA’s effects (often described as increasing openness, connection, and reducing fear responses) may help some people engage more effectively with trauma processing during therapy. 

What is PTSD?

Post-traumatic stress disorder (PTSD) is a mental health condition that can develop after someone experiences or witnesses a traumatic event that threatens life, safety, or physical integrity — such as serious accidents, violence, abuse, natural disasters, war, or sexual assault.

Not everyone who goes through trauma gets PTSD, but for those who do, symptoms must last more than one month and cause significant distress or problems in daily life for a diagnosis.

PTSD symptoms typically fall into four categories:

1. Intrusion (flashbacks, nightmares, unwanted distressing memories)
2. Avoidance (staying away from reminders of the trauma)
3. Negative changes in mood/cognition (persistent negative beliefs or emotional numbness)
4. Changes in arousal/reactivity (being easily startled, irritable, or having difficulty sleeping).

PTSD can happen at any age and is often accompanied by other mental health issues like depression or anxiety.

How common is PTSD in Canada?

In Canada, large national surveys show that a significant portion of adults have experienced traumatic events and many report PTSD symptoms:
• About 64% of Canadian adults report experiencing at least one potentially traumatic event in their lifetime.
• Approximately 7.7% of adults report having received a professional PTSD diagnosis at some point in their lives, and 6.1% currently have a diagnosis.
• When using a screening tool for symptoms (not necessarily a clinical diagnosis), 8.5% of adults show moderate to severe PTSD symptoms.

Differences by group:
• Women screen positive at higher rates (about 9.9%) than men (about 7.0%).
• Younger adults (ages 18–24) show higher symptom rates (~13.3%) than older adults (e.g., ~3.0% for those aged 65+).

How common is PTSD in the United States?

In the United States, PTSD affects a notable portion of the population, with important differences by gender and age:
• National estimates indicate that about 3.5–4% of U.S. adults have PTSD in a given year.
• Lifetime prevalence — the percentage who will experience PTSD at some point — is around 6–7% of U.S. adults.

Gender differences:
• Women are more likely to experience PTSD than men. U.S. data show females around 5.2% past-year prevalence compared with 1.8% for males, and lifetime rates are higher for women.

Adolescents:
• Around 8% of U.S. adolescents (ages 13–18) may experience PTSD at some point.

What are the most recent clinical trial results for MDMA therapy for PTSD?

A key recent result is the confirmatory Phase 3 randomized, placebo-controlled trial (MAPP2) published in Nature Medicine (Sept 2023). In this study, MDMA-AT produced a larger improvement in clinician-rated PTSD severity (CAPS-5) than placebo with therapy. By study end, 71.2% of participants in MDMA-AT no longer met PTSD diagnostic criteria (vs 47.6% in placebo+therapy);

What are the traditional therapies for PTSD, and how do they differ from MDMA therapy in effectiveness?

Traditional, evidence-based PTSD care most often involves trauma-focused psychotherapies (the “gold standard”), and sometimes medications such as SSRIs; however, many patients still have significant symptoms, and dropout can be a challenge. The Nature Medicine Phase 3 paper notes that despite gold-standard trauma-focused therapies, many individuals have persistent symptoms, and that even with FDA-approved SSRIs (sertraline, paroxetine), a substantial minority do not respond. 

MDMA-AT differs mainly in how therapy is delivered: it pairs psychotherapy with a few intensive, supervised MDMA sessions plus structured preparation/integration. MDMA-assisted psychotherapy shows promise even in some treatment-resistant PTSD populations, while emphasizing the need to weigh benefits and risks carefully.

How can MDMA therapy for PTSD be accessed?

Right now, access to MDMA-assisted therapy (MDMA-AT) for PTSD is mostly limited to research pathways because it is not approved for general clinical use either in the United States or Canada. In the U.S., the Department of Veterans Affairs notes that MDMA-AT can be studied in clinical trials, and Veterans interested in this treatment can look for approved trials (including within VA settings) as a legal route to participation. In Canada, Canada’s Health Canada Special Access Program (SAP) allows health-care practitioners to request authorized use of MDMA for individual patients with serious conditions (like treatment-resistant PTSD) on a case-by-case basis, subject to approval and strict oversight.

How do I buy MDMA Safely in Canada for MDMA-assisted psychotherapy for PTSD?

At Shroom Garden, we prioritize safety and transparency for those exploring MDMA for the first time, including for PTSD treatments. Our recommended products include:

Our MDMA Product Range:

• Amethyst Rock– Designed for balanced experiences centered around empathy and emotional connection, well-suited for therapeutic settings
• Champagne Rock – Known for enhancing physical sensation and tactile awareness
• Shamrock Rock – Fast-acting with enhanced visual perception, popular for immersive environments
• Clear Quartz Rock – Consistent profile promoting emotional openness and interpersonal connection
• Cola Rock – Energizing option for high-activity settings
• Darth Vader Rock – Potent option with intensified sensory and musical appreciation
• Pink Champagne Rock – Promotes verbal expression and social connection in intimate settings

All of our MDMA products are available in both rock crystal form and also pill form, depending on your preferred dosage.

Quality & Safety Standards:

Every product undergoes rigorous third-party laboratory testing to verify purity, potency, and dosage accuracy. These tests confirm that each batch is free from harmful contaminants. We make these results available to our customers as part of our commitment to transparency and harm reduction.

We require strict age verification before any purchase is completed, ensuring only adults of legal age can access our offerings in compliance with all relevant laws and regulations.

Ready to Order?

Our customer service team is available to answer questions about product specifications, testing results, and harm reduction practices. For those interested in exploring MDMA in therapeutic contexts, we encourage reviewing our educational resources on MDMA harm reduction,  MDMA therapy and clinical research.